These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 16189291

  • 21. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [Abstract] [Full Text] [Related]

  • 22. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Dec; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, Zimmer C, Orlandi C, Konstam MA.
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [Abstract] [Full Text] [Related]

  • 26. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, Fujiki H, Miyazaki S.
    Circ Heart Fail; 2012 Jul 01; 5(4):484-92. PubMed ID: 22628529
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK, Gustafsson F.
    Handb Exp Pharmacol; 2017 Jul 01; 243():307-328. PubMed ID: 28432473
    [Abstract] [Full Text] [Related]

  • 31. [Vasopressin receptor antagonists and heart failure].
    Haass M.
    Ther Umsch; 2009 Nov 01; 66(11):735-40. PubMed ID: 19885790
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure.
    Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB.
    J Am Coll Cardiol; 2000 Jan 01; 35(1):56-9. PubMed ID: 10636259
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M.
    J Cardiol; 2012 Dec 01; 60(6):462-9. PubMed ID: 23068288
    [Abstract] [Full Text] [Related]

  • 39. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, de Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B.
    Circ Heart Fail; 2009 Nov 01; 2(6):523-31. PubMed ID: 19919976
    [Abstract] [Full Text] [Related]

  • 40. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Takahashi A.
    Cardiovasc Drugs Ther; 2014 Feb 01; 28(1):73-7. PubMed ID: 24048511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.